(Q35638509)

9 August 2017

title

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis (English)

1 reference

Irene van der Horst-Bruinsma

9 August 2017

author

5

object named as

I van der Horst-Bruinsma

1 reference

9 August 2017

Désirée van der Heijde

1

object named as

D van der Heijde

1 reference

9 August 2017

J C Da Silva

2

1 reference

9 August 2017

M Dougados

3

1 reference

9 August 2017

P Geher

4

1 reference

9 August 2017

X Juanola

6

1 reference

9 August 2017

I Olivieri

7

1 reference

9 August 2017

F Raeman

8

1 reference

9 August 2017

L Settas

9

1 reference

9 August 2017

J Sieper

10

1 reference

9 August 2017

J Szechinski

11

1 reference

9 August 2017

D Walker

12

1 reference

9 August 2017

M-P Boussuge

13

1 reference

9 August 2017

J S Wajdula

14

1 reference

9 August 2017

L Paolozzi

15

1 reference

9 August 2017

S Fatenejad

16

1 reference

9 August 2017

Etanercept Study 314 Investigators

17

1 reference

9 August 2017

language of work or name

English

0 references

publication date

12 September 2006

1 reference

Annals of the Rheumatic Diseases

9 August 2017

published in

1 reference

9 August 2017

volume

65

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1572-1577

1 reference

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798458

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

25 September 2018

1 reference

12 December 2020

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

1 reference

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

12 December 2020

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

12 December 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

12 December 2020

Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice

1 reference

12 December 2020

Bath Ankylosing Spondylitis Functional Index

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2006.056747

1 reference

9 August 2017

1 reference

9 August 2017

1 reference